PolyActiva Pty. Ltd, a private “delivery from device” company, based in Melbourne, Australia, has announced the receipt of $9.2M in a Series B investment round. The funds are expected to support the completion of clinical proof-of-concept testing for the company’s drug polymer conjugate programmes. The company’s technology platform is built on enabling site-specific drug delivery from medical device components, such as implants, films or fibres.